Literature DB >> 10742982

Multidrug-resistance transporters.

J A Silverman1.   

Abstract

P-glycoprotein was initially isolated due to its role in multidrug resistance to cancer chemotherapeutics. Recent work, however, makes it increasingly apparent that this transporter is also involved in the pharmacokinetics of many drugs. P-gp is strategically expressed in the luminal epithelial cells of organs often associated with drug absorption and disposition, for example, hepatocyte canalicular membrane, renal proximal tubules, and the intestinal mucosa. P-gp is also expressed in the endothelial cells comprising the blood-brain barrier. This localization clearly suggests the potential for this protein to serve as a protective mechanism against entry of toxic xenobiotics and also suggests that P-gp is well situated to participate in the removal of therapeutic agents. Numerous investigations with drugs such as digoxin, etoposide, cyclosporine, vinblastine, Taxol, loperamide, dom-peridone, and ondansteron demonstrate that P-gp has an important role in determining the pharmacokinetics of substrate drugs. Pharmacological modulation of P-gp function to increase drug bioavailability, both on a organismal and a cellular level, is one approach currently being explored to enhance therapeutic effectiveness. This approach is not without potential collateral consequences given the wide tissue distribution of P-gp. While animals deficient in P-gp are viable and without obvious abnormalities, the pharmacokinetics and toxic consequences of several compounds are significantly altered in these animals. Thus blockade of the protective P-gp barrier in humans may have adverse effects on substrate drugs. In particular, this situation may arise when several compounds which may be substrates compete for P-gp-mediated transport. Additional multidrug transporters, notably MRP and family members, have been identified and may also determine the fate of pharmaceuticals. Further understanding the physiological role of each of the multidrug transporters is critical for determining their role in pharmacokinetics and for evaluating the consequences of modification of their activities. Such information is also important in the development of novel drugs which may be substrates for these transporters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10742982     DOI: 10.1007/0-306-46812-3_13

Source DB:  PubMed          Journal:  Pharm Biotechnol        ISSN: 1078-0467


  14 in total

Review 1.  Pharmacogenomics and systems biology of membrane transporters.

Authors:  Qing Yan
Journal:  Mol Biotechnol       Date:  2005-01       Impact factor: 2.695

Review 2.  Blood-brain barrier active efflux transporters: ATP-binding cassette gene family.

Authors:  Wolfgang Löscher; Heidrun Potschka
Journal:  NeuroRx       Date:  2005-01

3.  Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Authors:  Konstantin Kuteykin-Teplyakov; Carlos Luna-Tortós; Kamila Ambroziak; Wolfgang Löscher
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

Review 4.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 5.  Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies.

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Mariko Matsumoto; Tsutomu Urano; Ryuichi Hasegawa
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Application of pharmacological approaches to plant-mammal interactions.

Authors:  Jennifer S Sorensen; Michele M Skopec; M Denise Dearing
Journal:  J Chem Ecol       Date:  2006-05-23       Impact factor: 2.626

7.  Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases.

Authors:  Dominik Gartzke; Jürgen Delzer; Loic Laplanche; Yasuo Uchida; Yutaro Hoshi; Masanori Tachikawa; Tetsuya Terasaki; Jens Sydor; Gert Fricker
Journal:  Pharm Res       Date:  2014-12-19       Impact factor: 4.200

8.  Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters.

Authors:  Maciej Kaliszczak; Dyeison Antonow; Katan I Patel; Philip Howard; Duncan I Jodrell; David E Thurston; Sylvie M Guichard
Journal:  AAPS J       Date:  2010-08-12       Impact factor: 4.009

9.  Mana-Hox displays anticancer activity against prostate cancer cells through tubulin depolymerization and DNA damage stress.

Authors:  Che-Jen Hsiao; Yunn-Fang Ho; John T-A Hsu; Wei-Ling Chang; Yi-Cheng Chen; Ya-Ching Shen; Ping-Chiang Lyu; Jih-Hwa Guh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-29       Impact factor: 3.000

10.  Rhodamine 123 requires carrier-mediated influx for its activity as a P-glycoprotein substrate in Caco-2 cells.

Authors:  Matthew D Troutman; Dhiren R Thakker
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.